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Abstract: Neuropsychiatric diseases ranging from schizophrenia to affective disorders and 
autism are heritable, highly complex and heterogeneous conditions, diagnosed purely 
clinically, with no supporting biomarkers or neuroimaging criteria. Relying on these 
“umbrella diagnoses”, genetic analyses, including genome-wide association studies 
(GWAS), were undertaken but failed to provide insight into the biological basis of these 
disorders. “Risk genotypes” of unknown significance with low odds ratios of mostly <1.2 
were extracted and confirmed by including ever increasing numbers of individuals in large 
multicenter efforts. Facing these results, we have to hypothesize that thousands of genetic 
constellations in highly variable combinations with environmental co-factors can cause the 
individual disorder in the sense of a final common pathway. This would explain why the 
prevalence of mental diseases is so high and why mutations, including copy number 
variations, with a higher effect size than SNPs, constitute only a small part of variance. 
Elucidating the contribution of normal genetic variation to (disease) phenotypes, and so  
re-defining disease entities, will be extremely labor-intense but crucial. We have termed 
this approach PGAS (“phenotype-based genetic association studies”). Ultimate goal is the 
definition of biological subgroups of mental diseases. For that purpose, the GRAS 
(Göttingen Research Association for Schizophrenia) data collection was initiated in 2005. 
With >3000 phenotypical data points per patient, it comprises the world-wide largest 
currently available schizophrenia database (N > 1200), combining genome-wide SNP coverage 
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and deep phenotyping under highly standardized conditions. First PGAS results on normal 
genetic variants, relevant for e.g., cognition or catatonia, demonstrated proof-of-concept. 
Presently, an autistic subphenotype of schizophrenia is being defined where an unfortunate 
accumulation of normal genotypes, so-called pro-autistic variants of synaptic genes, 
explains part of the phenotypical variance. Deep phenotyping and comprehensive clinical 
data sets, however, are expensive and it may take years before PGAS will complement 
conventional GWAS approaches in psychiatric genetics. 
Keywords: mental disease; diagnosis; classification systems; GWAS; monozygotic twins; 
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1. Schizophrenia Is a Heterogeneous Group of Diseases Diagnosed Purely Clinically 
The diagnosis of schizophrenia (as of most mental diseases) is to this day an exclusively clinical 
one which, based on the leading classification systems, DSM and ICD, demands the simultaneous 
presence of a number of symptoms that are labeled “positive” or “negative”. In addition, persistence of 
these symptoms for at least 6 months is requested. As such, schizophrenia is the unifying term of a 
highly complex and heterogeneous group of multigenetic disorders, with an array of environmental 
hazards having influenced onset and course. Common to this group of disorders are merely some gross 
phenotypical traits. Biomarkers in unequivocal support of the diagnosis are missing and also modern 
imaging technologies, despite revealing brain matter loss or various functional alterations, have not yet 
assisted in better understanding disease etiology or pathogenesis, or in defining objective diagnostic 
criteria. This conglomerate of uncertainties, however, is the groundwork on which genetic studies have 
been and are being built on. 
2. Despite High Heritability of Schizophrenia No “Disease Genes” Have Been Uncovered 
There is no doubt that schizophrenia has a major genetic root. Family studies yielded heritability 
estimates of up to 80% for schizophrenia [1,2]. Monozygotic twins manifest concordance rates of 
~50%, thus—on top of a clear genetic origin—pointing to a considerable influence of non-genetic 
causes, i.e., environmental and/or epigenetic factors [3–6]. Searching for the genetic part of 
schizophrenia etiology, a considerable number of explorations have been undertaken, ranging from 
segregation or linkage analyses to association studies based on candidate genes [7,8]. Most of the so 
identified “disease genes”, e.g., DISC1 [9], turned out not to respect disease borders. In fact, the DISC1 
translocation was found associated as much with mental health as with affective diseases, 
schizophrenia, autism, or personality disorders [10]. DISC1 and others may thus at best deserve the 
label of a global risk gene for mental disorders. 
So far, no definite “schizophrenia genes” of general significance could be identified. Recently 
reported genome-wide association studies (GWAS) of schizophrenia identified a number of genetic 
risk markers significantly associated with the disease, but unfortunately could not extract any universally 
convincing “disease genes”. The initially limited reproducibility over studies and ethnicities has 
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improved with increasing numbers to ~60,000 individuals (PGC, Psychiatric Genetic Consortium) [11]. 
Associations, however, remain hampered by very low odds ratios (OR distinctly <1.2) [12,13]. 
Altogether, it appears highly unlikely that even larger GWAS, based on the umbrella term 
“schizophrenia”, will succeed in unraveling the genetic basis of these conditions or in identifying 
relevant disease genes. 
3. “GWAS Hits” Do Not Predict Disease Severity or Other Relevant Schizophrenia Phenotypes 
Which information do we then gain from the GWAS-identified risk genotypes? In fact, even an 
accumulation of the GWAS-identified “top 10” risk genotypes [14] does not lead to a more severe 
disease phenotype. In other words: If an individual possessed all “top 10” risk markers at the same 
time (“accumulated risk”), his disease will not be more grave than if he carried none of the  
risk genotypes. 
Another attempt to make use of the GWAS-derived information has been the definition of 
polygenic schizophrenia risk scores (PSS). Besides the genome-wide significant risk loci, a substantial 
proportion of schizophrenia risk has been hypothesized to lie in markers not achieving genome-wide 
significance. Thus, quantitative PSS were calculated based on nominal associations of each SNP from 
the PGC GWAS. These PSS explained up to 6% of variance regarding the diagnosis schizophrenia in 
an independent sample [11]. Subsequently, PSS effects on various disease-relevant phenotypes, e.g., 
brain matter dimensions, were explored with variable success [15,16]. Employing the GRAS data 
collection of >1200 well characterized schizophrenic subjects (see below), we could not uncover the 
slightest association of PSS with any lead features of schizophrenia. In contrast, we found in the same 
schizophrenic population dramatic effects of accumulated environmental risk on age at onset of the 
disease [17]. 
4. Definition of Biological Subgroups of Schizophrenia: The Essential Next Step 
In summary, we note that all genetic “schizophrenia markers” discovered by GWAS up to date do 
not contribute more to the entirety of this disease than a minimally heightened probability (OR <1.2) 
of receiving the “umbrella diagnosis schizophrenia”. This whole picture could, however, look quite 
different when considering biological subgroups of schizophrenia as illustrated in Figure 1. GWAS on 
well-defined disease-relevant subphenotypes may ultimately not only lead to the identification of 
entirely new risk genotypes but, importantly, also to a re-distribution of some of the identified GWAS 
risk markers to certain subgroups, resulting then in much higher odds ratios. 
In order to define biological subgroups of schizophrenia, the GRAS (Göttingen Research 
Association for Schizophrenia) data collection was initiated in 2004 [18,19]. The lead hypothesis of 
GRAS states that schizophrenia is caused by thousands of possible combinations of genetic markers 
interacting with a large array of different environmental risk factors. There may be rare cases where a 
‘per se’ critical genetic load exists and the disease onset is independent of additional external factors. 
In the vast majority of cases, however, only the interaction between certain genetic predispositions and 
environmental factors will lead to disease onset. The overlap of genetic risk factors between individual 
schizophrenic patients/families probably is fairly low. This in turn might explain why it is obviously 
impossible to obtain common risk genes of schizophrenia with convincing odds ratios. According to 
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the primary GRAS hypothesis, schizophrenia is the result of a combination of ‘unfortunate’ normal 
genetic variants exposed to unfavorable environmental influence. Apart from its scientific significance, 
undoubtedly, this hypothesis strongly supports any anti-stigma campaign. 
Figure 1. Schematic presentation of three hypothetical subphenotypes of schizophrenia 
embedded in a sample Manhattan plot. The non-overlapping red, blue or yellow dots 
comprise genetic constellations (“assemblies”) suggested to account for disease subforms 
with respective subphenotypes. Note that typical genome-wide association studies 
(GWAS) “top hits”, as defined by the highest significance levels for the clinical endpoint 
diagnosis (“schizophrenia”), most likely fall into different assemblies. This can explain 
their low odd ratios in a large and diverse patient group and the apparent lack of 
interactions. The depicted schema is purely hypothetical and shall illustrate the difficulties 
to define disease genes by conventional GWAS approaches based on endpoint diagnoses. 
 
We hypothesize that a considerable proportion of the population across cultures (likely ~50%) may 
harbor a principal genetic make-up for developing mental diseases whereas the remaining 50% of 
individuals could never acquire them due to absence of respective genetic prerequisites. Only in a small 
fraction of risk carriers the disease will break out (~0.5%–1% of the population across cultures) [20],  
co-induced by a multitude of potential external inputs, while the bulk of carriers will stay healthy and 
forward their predisposition to their offspring. 
5. Deep Phenotyping Is a Prerequisite for PGAS: The GRAS Data Collection 
If all human genetic approaches to schizophrenia as a “classic” genetic disease apparently failed, 
how will it be possible to learn more about the contribution of genes/genotypes to relevant disease 
subphenotypes? Motivated by this central question we started an alternative and at the same time 
complementary approach to conventional GWAS. We call this approach PGAS, which stands for 
phenotype-based genetic association study. PGAS enables us to explore the contribution of 
genes/genetic markers to schizophrenic subphenotypes. To start PGAS, we had to establish a 
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comprehensive standardized phenotypical characterization of schizophrenic patients, the above 
introduced GRAS data collection. Within a few years we compiled the presently world-wide largest 
phenotypical database of schizophrenic patients comprising presently ~1200 subjects, with slow 
steady-state recruitment ongoing. Although much larger data bases of schizophrenic subjects exist, 
unfortunately, they do not even come close to the deep phenotyping information of GRAS. A total of 
23 psychiatric hospitals all over Germany were involved as hosting centers in this effort [18,19]. 
Inclusion criteria for the patients were confirmed diagnosis of schizophrenia or schizoaffective 
disorder, and the ability to cooperate at least to a minimal degree. The GRAS population is 
representative for those schizophrenic patients in central Europe/Germany who are in contact with the 
healthcare system. Unrivalled in the GRAS data collection is the fact that all cross-sectional 
examinations of all patients were performed by one and the same travelling team. This fact contributes 
in a highly significant manner to the homogeneity of the resulting database, containing at present 82% 
schizophrenic and 18% schizoaffective subjects [18,19]. 
The GRAS data collection does not only encompass sociodemographic and basic clinical 
parameters but also, for example, a very comprehensive cognitive test battery, an extensive 
investigation of neurological signs and symptoms, a thorough medication history, several tests of 
extrapyramidal side effects of antipsychotic medication, complete information on drug abuse/addiction 
or other comorbidities, to name just a few of the covered data modules. Apart from the comprehensive 
cross-sectional analyses, we collected nearly all psychiatric medical reports and discharge letters of all 
GRAS patients, allowing also for fairly solid longitudinal data analysis, e.g., information on disease 
course and outcome. Altogether, we have about 3000 data points per patient, which allow us to 
perform PGAS [18,19]. Importantly, most GRAS patients agreed to be re-contacted for follow-up 
studies, thereby enabling targeted analyses in the future, e.g., detailed morphometrical or functional 
magnetic resonance imaging studies, or inducible pluripotent stem cell approaches to study cellular 
consequences of complex genotypes. 
6. Phenotype-Based Genetic Association Studies (PGAS): Proof-of-Principle 
First proof-of-principle studies for the PGAS approach were performed over the last years. We 
could show that genetic variants within the complexin2 gene (6 single nucleotide polymorphisms) 
influence the cognitive capability of schizophrenic patients [18]. This gene encodes a synaptic protein 
that is crucial for the regulation of neurotransmitter release. Similarly, the calcium-activated potassium 
channel SK3 is involved in the modulation of neuroplasticity and influences cognition of schizophrenic 
individuals genotype-dependently (as a function of the length of a CAG repeat in the N-terminal 
region) [21]. Moreover, a distinct combination of erythropoietin (EPO) and EPO receptor (EPOR) 
genotypes leads to a remarkable cognitive benefit in schizophrenic subjects as compared to all other 
possible EPO/EPOR genotype combinations [22]. Of note, the association of certain genetic variants 
with cognition in schizophrenia may likewise hold true for healthy individuals and other disease 
populations [22]. This clearly emphasizes the importance of investigating the genotype contribution to 
phenotypes in general, rather than immediately focusing on risk genes in complex diseases. 
Among the discussed candidate risk genes of schizophrenia is NRG1 [23–25]. Analyzing its 
disease-relevance in the GRAS population yielded for the first time an association with age at disease 
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onset and severity of positive symptoms [26]. A myelin-associated gene, CNP, turned out to  
co-determine the occurrence of a catatonia-depression syndrome upon aging [27]. Importantly, in most 
of these PGAS approaches, either replication in an independent human cohort and/or behavioral 
phenotypes in corresponding mouse mutants were demonstrated. In fact, the translation to mouse 
models, and even to cultured cells, plays an important part in the search for mechanistic 
comprehension of the observed phenomena. 
7. PGAS Will Be Instrumental for Definition of Biological Schizophrenia Subgroups 
Even though the above mentioned first proof-of-principle studies were important to set the stage for 
PGAS, it is now mandatory to work on the “bigger picture”. The availability of genome-wide genetic 
data on the GRAS sample enables us to better understand the genetic basis of neuropsychiatric 
phenotypes. Using the AxiomTM Caucasian European array as a backbone, we have enriched it by 
including additional markers of putative functional importance [28]. At present, we are in the process 
of defining biological subphenotypes of schizophrenia which are less complex as compared to the 
‘umbrella diagnosis schizophrenia’ and can be described and well quantified by respective phenotype 
scores. Prerequisite for applying these scores to genetic studies is a high internal consistency of the 
selected score items, reflected by a demanded Cronbach’s alpha of >80%. As a first example, we have 
operationalized an autistic subphenotype of schizophrenia. This subphenotype, which comprises lead 
features of high-functioning autism (deficits in social interaction and communication, as well as 
repetitive behaviors/stereotypies), shows a normal distribution in the GRAS population, thus allowing 
for extreme group comparisons with respect to the associated genotypical information. Our primary 
target genes for the autistic subphenotype are synaptic genes where we find an unfortunate 
accumulation of normal genotypes, that we consider as “pro-autistic” variants of these genes, to 
explain an appreciable part of the phenotypical variance. A sample of Asperger autists is presently 
recruited with the aim to replicate the genotype-phenotype associations found in the autistic subgroup 
of schizophrenic individuals. Similarly, a psychomotor and a schizoaffective subphenotype of 
schizophrenia will be phenotypically as well as—subsequently—genetically characterized, targeting 
myelin- and ion channel-associated genes, respectively [29]. 
8. Conclusions 
To conclude, the lack of objective diagnoses and the non-existence of classical disease genes have 
forced us to re-consider the genetic approach to mental diseases. Deep clinical phenotyping as 
prerequisite for PGAS, combined with genome-wide SNP coverage, makes it possible to improve our 
understanding of the molecular-genetic architecture of schizophrenia and likely other mental diseases 
via systematic phenotype-based approaches. These in turn necessitate highly labor-intense groundwork 
since they depend on the availability of comprehensive phenotypical databases comparable to the 
GRAS data collection. Some efforts in a similar direction are launched in other disciplines, for instance 
in a first trial to integrate available electronic medical record data and GWAS information [30]. 
Regarding the depth of phenotyping, however, this approach certainly needs to be substantially 
improved. Even if “deep phenotyping” is much more tedious than collecting thousands of subjects with 
merely a certain diagnostic label versus healthy individuals, it will be the only way to reach the goal, 
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i.e., novel definitions of biologically sound disease subgroups. It can only be hoped that big consortia 
and sponsors will follow this rationale such that the number of deeply phenotyped individuals will 
grow. At the end of the road, PGAS will permit better insights into the complex genotype-phenotype 
interactions of schizophrenia (and other neuropsychiatric diseases) and in this way open up more 
targeted therapeutic strategies for biological subphenotypes of the disease. 
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